If there was one thread running through ESCMID Global 2026, it was this: diagnostics are advancing quickly – but are we ready for what they enable?
Across sessions, conversations kept circling back to the same tension. We all want faster answers. But speed, on its own, is not the goal.
Heiman Wertheim captured this balance succinctly in his talk on Saturday, focused on diagnostic stewardship: “We need more rapid tests, but not at the cost of quality.” It’s a sentiment that resonated widely – particularly as laboratories face increasing pressure to deliver results in ever shorter timeframes.
Evelina Tacconelli pushed the discussion further, asking a question that lingered throughout the meeting: “Are we improving care with rapid diagnostics or accelerating processes we aren’t prepared to perform?”
It’s a challenge that will feel familiar to many pathologists and laboratory medicine professionals. Rapid diagnostics can shorten time to result – but unless clinical pathways, antimicrobial stewardship, and reporting systems are aligned, those faster answers may not translate into better outcomes.
Persistent challenges: sepsis and AMR
Two areas repeatedly highlighted were neonatal sepsis and antimicrobial resistance (AMR). Despite years of innovation, both remain difficult from a diagnostic perspective.
In neonatal sepsis, the stakes are particularly high. Small sample volumes, low pathogen loads, and the need for rapid intervention continue to complicate testing. Meanwhile, AMR adds another layer of complexity – requiring not just identification of pathogens, but timely and accurate susceptibility data.
Layered on top of this is a familiar constraint: doing more with less. Laboratories are being asked to deliver faster, more comprehensive diagnostics, often without corresponding increases in resources.
New tools, familiar questions
The “Year in Clinical Microbiology” session offered a snapshot of emerging diagnostic approaches. Notably, several technologies are moving beyond traditional sequencing-based methods.
Ultra-rapid nanoplasmonic colorimetry and nanomotion-based systems are being developed to detect pathogens or antimicrobial susceptibility in very short timeframes. Raman micro-spectroscopy is also gaining attention as a culture-free approach, potentially enabling direct-from-sample pathogen identification.
At the same time, AI is becoming more embedded in microbiology workflows. Tools such as CarbaDetector and deep learning imaging approaches – like structured illumination microscopy – are being used to support detection and classification. MALDI-TOF mass spectrometry continues to expand its role, with applications now extending into AMR detection and bloodstream infection screening, including in pediatric settings.
There is also growing interest in non-phenotypic diagnostics. Metagenomic approaches and AI-integrated platforms are being clinically benchmarked, with the aim of improving detection breadth and reducing time to diagnosis. But as several speakers noted, integration into routine workflows remains a significant hurdle.
Beyond the bench: systems and regulation
Some of the most forward-looking discussions moved beyond individual technologies.
Digital twins – computational models that simulate biological systems – are beginning to appear in AI regulatory submissions and virtual screening. While still early in their adoption, they point to new ways of validating and assessing diagnostic tools.
Regulatory convergence was another key theme. There is increasing recognition that international alignment will be necessary to support the safe and timely adoption of new diagnostics, particularly those that combine molecular testing, AI, and complex data interpretation.
And underpinning much of the AMR discussion was the One Health perspective. Diagnostics are no longer viewed in isolation; instead, they are part of a broader ecosystem that spans human, animal, and environmental health.
Where does this leave the lab?
For all the innovation on display, ESCMID Global 2026 offered a clear message: diagnostics cannot be evaluated in isolation.
Faster tests are valuable – but only if they deliver reliable results, integrate into clinical workflows, and ultimately support better decision-making. Without that, there is a risk of creating bottlenecks further downstream.
For laboratory professionals, the challenge is not just adopting new technologies, but ensuring they are used in ways that improve patient care. That means maintaining quality, validating new approaches rigorously, and working closely with clinical teams to ensure that diagnostic advances translate into meaningful outcomes.
The tools are evolving quickly. The question, as Tacconelli suggested, is whether our systems are evolving at the same pace.
Newsletters
Receive the latest pathologist news, personalities, education, and career development – weekly to your inbox.
